Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
CPI 613: Transforming Pancreatic Cancer Treatment
CPI-613 (Devimistat) | ≥99%(HPLC) | Selleck | デヒドロゲナーゼ 阻害剤
Figure 1 from A phase 1 study of first-in-class agent CPI-613 in ...
Devimistat (CPI-613) – 美仑生物
Devimistat (CPI-613) | CAS 95809-78-2 | AbMole BioScience | Devimistat ...
CPI-613 induces reactive oxygen species-mediated glutathionylation and ...
Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer ...
CPI-613 in combination with CHC leads to a reduction in pancreatic ...
CPI-613 (Devimistat) | 购买Dehydrogenase 抑制剂 - Selleck
Devimistat(CPI-613)
Devimistat (CPI-613) | Mitochondrial Metabolism Inhibitor | MedChemExpress
Table 1 from The Mitochondrial Disruptor Devimistat (CPI-613 ...
Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin ...
“饿死”癌细胞！线粒体三羧酸循环靶向药物devimistat(CPI-613）治疗胰腺癌和白血病(AML)3期临床失败! - 专区 - 生物谷
Devimistat (CPI-613) | 线粒体代谢抑制剂 | MCE
The Mitochondrial Disruptor Devimistat (CPI-613) Synergizes with ...
Devimistat (CPI-613) | PDH/-KGDH Inhibitor - DKM中国
PRELIMINARY ACTIVITY OF DEVIMISTAT (CPI 613) IN PATIENTS WITH RELAPSED ...
Devimistat (CPI-613) | 购买Dehydrogenase 抑制剂 - Selleck
CPI-613 in combination with galloflavin inhibits pancreatic cancer cell ...
A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and ...
Figure 1 from Targeting Cellular Metabolism With CPI-613 Sensitizes ...
CPI-613 induces apoptosis in pancreatic cancer cells. a, b The effects ...
CPI-613 (Devimistat) | Dehydrogenase 抑制剂 | CPI-613 (Devimistat)供应商 AdooQ®
Rafael Pharmaceuticals、Devimistat（CPI-613®）での遠隔転移を有する膵臓がん患者を対象としたピボタル第3 ...
In vitro assessment of the combination of CPI-613 with... | Download ...
CPI-613 (Devimistat) | Dehydrogenase Inhibitor | 95809-78-2 | AdooQ®
Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b ...
CPI-613 promotes the AMPK-ULK1 autophagic signaling in pancreatic ...
The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian ...
The effects on apoptosis of free CPI-613 and CPI-613-loaded TTCI NPs at ...
Rafael Pharmaceuticals Announces the Initiation of a Phase 1b/2 ...
CPI-613线粒体靶向小分子前药及其自组装纳米粒、制备方法和应用_2
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613 ...
CPI-613 (Devimistat): How This Anti-Cancer Drug Targets Mitochondria
PanCAN Awards
CPI-613 | Devimistat | PDH inhibitor | Axon 2125 | Axon Medchem
Apoptosis related antagonist | Apoptosis related inhibitor | Apoptosis ...
CPI-613 induces the morphological changes of mitochondrial and inhibits ...
CPI-613 induces a strong mitochondrial burst of reactive oxygen species ...
CPI-613 inhibits α-ketoglutarate dehydrogenase activity selectively in ...
GLS1 depletion sensitizes HNSCC cells to CPI-613. A The effect of GLS1 ...
Therapeutic potential of CPI-613 for targeting tumorous mitochondrial ...
Evidence for a novel, effective approach to targeting carcinoma ...
CPI-613 inhibits lipid metabolism through suppressing ACC activity in ...
Smart Design of Mitochondria-Targeted and ROS-Responsive CPI-613 ...
Pretreatment with CPI-613 negates the olaparib-induced increase in ...
CPI-613 induced autolysosome formation in HS-MM CCS cells. DALGreen ...
Addition of CB-839 strengthens the cytotoxic effect of CPI-613 ...
CPI-613-induced mitochondrial reactive oxygen species originate from a ...
(PDF) Targeting cellular metabolism with CPI-613 sensitizes pancreatic ...
CPI-613 – Metabolic Inhibitor | APExBIO
(PDF) The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of ...
Targeting mitochondrial metabolism with CPI-613 in chemoresistant ...
Combinational in vivo treatment of CPI-613 and carboplatin/paclitaxel ...
In Vitro and In Vivo Metabolism of a Novel Antimitochondrial Cancer ...
(PDF) CPI-613 Suppresses Pancreatic Cancer Stem-Like Cells by Targeting ...
